Drug Profile
Research programme: anticancer antibodies - Bristol-Myers Squibb/QIMR Berghofer Medical Research Institute
Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; QIMR Berghofer Medical Research Institute
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer